Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile
New York, New York–(Newsfile Corp. – February 7, 2023) – Soulstring Media Group, Llc., a market research, aggregator, and digital media production and management company specializing in creating and syndicating content from publicly traded and private companies, announced today that it had published an in-depth interview with Acurx Pharmaceuticals (NASDAQ: ACXP) President and CEO, Mr. David Luci. The interview discusses ACXP’s ongoing Phase 2b trial utilizing ibezapolstat to treat C. difficile and why he believes his company is positioned to deliver a front-line treatment for the debilitating disease. To view the entire interview, along with disclosures and disclaimers, please follow this link:
FULL…
